I don't expect these early gains to hold in a down 200 market. If we stay above $15, that will be a win today IMO unless the market reverses. The quarterly "profit" was based on recognizing revenues from past licensing efforts, for which the cash has already been received. Cash burn will be lower due to 901 failure, no additional costs. There's really nothing new here. Clinical progress continues at a snail's pace. Not impressed with Charlie, he blathers worse than Dan on the calls. Look for selling on the open. Those who bought in the premarket will be sorry. I sold some at $16.1 will buy back under $15 today IMO.